Gara Jalqabaatti › Kansa Endometiriyaalii › Tennessee
Qorannoo klinikaalii Kansa Endometiriyaalii Tennessee keessatti
Qorannoo 40 Kansa Endometiriyaalii f Tennessee keessatti hirmaatuu jiru.
Magaalota Tennessee keessatti
Takkalaa qorannoo (Ingiliffa)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Vanderbilt-Ingram Cancer Center Cool Springs, Franklin
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 05-Onk-2026 · NCT07198074Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Regional Cancer Center at Johnson City Medical Center, Johnson City
- Ballad Health Cancer Care - Kingsport, Kingsport
- fi 3 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin hundi · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05564377A Study of PHST001 in Advanced Solid Tumors
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06840886A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06270706The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04585750A Phase 1 Study of the Safety and Tolerability of CTX-10726
- SCRI Oncology Partners, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07419841A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06760819A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06172478A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 19 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06586957DESTINY-PANTUMOUR04
- Research Site, Nashville
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 hanga 130 · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07124000Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06218914Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Nashville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 130 · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sarah Cannon - Tennessee Oncology, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT05983432A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Erlanger Medical Center ( Site 5009), Chattanooga
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 17-Ful-2026 · NCT06952504A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Sarah Cannon Nashville, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT07109726A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07213609Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT06293898Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Sarah Cannon Research Institute, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Dubartoota · Haaromfame 03-Ful-2026 · NCT07755436A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Vanderbilt-Ingram Cancer Center, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT06515613A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- SCRI Oncology Partners - Nashville, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 26-Hag-2026 · NCT07383506Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 15 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
Namoota walitti qabaa jiraSadarkaa 1/2
12 Months – 30 Years · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT04851119A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT07182149FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT05919264A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT05592626A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Hag-2026 · NCT06330064Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Tennessee Oncology, PLLC, Chattanooga
- SCRI Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ado-2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Knoxville
- Research Site, Nashville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 29-Ado-2026 · NCT07044336A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- SCRI Oncology Partners, Nashville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Ado-2026 · NCT06695845First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- The West Clinic, PLLC dba West Cancer Center, Germantown
- Sarah Cannon Research Institute, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Ado-2026 · NCT05768139A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT05377996A Study of LY4175408 in Participants With Advanced Cancer
- Sarah Cannon Research Institute, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Wax-2026 · NCT07046923A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- SCRI Oncology Partners, Nashville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Wax-2026 · NCT07503808Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Cam-2026 · NCT06239194cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 40 fi ol · Saalaa hunda · Haaromfame 20-Ama-2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Tennessee Oncology, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2025 · NCT05941507A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Gur-2025 · NCT05669430Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.